- Commercial Platform
- Healthcare Partners
- News & Resources
- Nasdaq: OPRX
- Press & Events
- Stock Information
- Investor Resources
- Schedule Demo
As the nation’s largest point-of-prescribe promotional platform for the pharmaceutical industry, OptimizeRx provides a direct channel for life sciences companies to communicate with healthcare providers right within their workflow - whether in the hospital or ambulatory setting. Coupled with our patient adherence applications, OptimizeRx empowers your brand to make better connections leading to better outcomes.
OptimizeRx can now deliver your Brand’s Financial Messaging to leading Health Systems and Hospitals.
We are committed to fill the communications gap between patients, providers, payers, and the pharmaceutical industry.
It’s about working with others who know the healthcare and pharmaceutical industries inside and out. By creating this collaborative approach, we can work together to break through.
Mr. Gus D. Halas served as the Chief Executive Officer and President of the Central Operating Companies of Central Garden & Pet Company (Central Garden & Pet Corp.) from April 2011 to June 2013.
Mr. Halas served as the President and Chief Executive Officer of T-3 Energy Services Inc. from May 2003 to March 2009.
He served as the Chief Executive Officer of Clore Automotive, Inc. from August 2001 to April 2003 and also served as its President. He also helped institute Kaizen and Lean Manufacturing principles on a global scale.
From January 2001 to May 2001, he served as the President at Marley Cooling Tower Company at United Dominion Industries Limited. From January 1999 to August 2000, he served as the President of Pump Services Group at Ingersoll-Dresser Pump Company.
From 1986 to 1999, he served in various management roles, including the Senior Vice President of Customer Support Services of Sulzer Industries Inc. He served at Sulzer, Ltd. He served as the Chief Executive Officer and President at Interpet Limited. He served as the President and Chief Operating Officer at Marley Cooling Industries and served as the President at Ingersoll-Dresser’s Pump Company. He served as a Partner and Member of Advisory Board of White Deer Energy. Mr. Halas served as the Chairman of T-3 Energy Services Inc., from March 2004 to April 2009 and as a Director from May 2003 to March 2009. He has been an Independent Director at Aquilex Holdings LLC since June 2007 and School Specialty, Inc. since July 2015. He has been a Director at Triangle Petroleum Corporation since October 2011 and Hooper Holmes Inc. since April 2013.
Mr. Halas has been a Director of OptimizeRx Corporation since August 2014 and Madalena Energy Inc. since January 2015. He served as a Director of Aquilex Corporation until July 2011.
He has significant experience in the energy industry and in public companies in both an executive and board role.
Mr. Halas holds an M.B.A. from Imede Lausanne Switzerland and a BS in Physics and Economics from Virginia Tech University.
Mr. Lang brings to OptimizeRx more than 25 years of experience in healthcare data, analytic, and technology enabled business services.
Lang presently serves as an executive advisor to Water Street, a strategic private equity firm focused exclusively on building market-leading companies in healthcare. He is also a director of BioVie, a development-stage company pioneering an innovative therapeutic that targets complications due to liver cirrhosis.
Previously, Mr. Lang served as CEO of Decision Resources Group, DRG, a leading healthcare research and consulting company providing high-value healthcare industry analysis and insights, where he helped transform the company into an industry leader. Earlier, he was president of Strategic Decisions Group, a premier global strategy consultancy, and he expanded the life sciences practice and later sold it to IMS Health.
He is an active private investor and advisor with healthcare companies, including Boston Heart Diagnostics (acquired by Eurofins) and AlphalmpactRx (acquired by IMS Health).
James Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire, and earned an MBA with distinction from the Tuck School of Business where he was named an Edward Tuck Scholar.
He currently guest lectures at the Tuck School of Business in strategy and decision-making.
Lynn is the President and CEO of the Muscular Dystrophy Association (MDA), the leader in the fight against muscular dystrophy and ALS through its funding of research, clinical care, support service, and education.
Lynn has a hands-on appreciation for patient care, and she has considerable executive experience and expertise in the fields of pharmacology, medical and clinical education, and digital marketing.
Prior to her arrival at MDA, Lynn was CEO of ghg | greyhealth group for nearly 23 years and is credited with creating, building and acquiring companies — specifically, nine acquisitions — to grow ghg’s global footprint. While at ghg, Vos led global expansion and diversification strategies and within two years grew the company from a small, domestic professional player into an award-winning global enterprise with fully integrated, multi-channel offerings.
She is a recognized thought leader in the industry with published white papers and articles outlining new, successful approaches to health care technology and communication.
Pat currently serves as Chief Financial Oﬃcer of VigiLanz Corporation, a privately held firm in health care information technology. Pat brings more than 30 years of experience in the healthcare industry, executing domestic and international growth and exit strategies. He has helped lead high-performance, emerging growth firms, as well as large publicly traded companies and has also served in the private equity sector successfully improving operational results with a broad array of portfolio companies.
Prior to VigiLanz Corporation, he served as Executive Vice President and Chief Financial Oﬃcer of Healthland, Inc. an EHR company serving the critical access hospital market; Epocrates (EPOC) which he took public in 2011 and was acquired by Athena Health, ev3 (EVVV) which he took public in 2005 and was acquired by Covidien, and EMPI (EMPI) which was acquired by Encore Medical (ENMC).
He currently is a member of the Board Of Directors of Lifespace Communities Inc and previously served on the Board Of directors of Urologix Inc. (ULGX).
Pat holds a B.S. in accounting and an M.B.T. in business taxation from the University of Minnesota and a M. B. A. from the University Of Chicago Booth Graduate School Of Business.
Connecting the Pharma & Healthcare industry with compliant innovation has been Febbo’s trademark in over 18 years of leading health service & technology companies.
In 1999, he co-founded MedPanel, a market intelligence and communication provider to the biomedical & medical device industries. When Febbo sold it in 2007 to Merriman Capital, he held dual roles as COO of the bank and CEO of Digital Capital Network which he launched pioneering digital compliance & transparency product in the financial industry.
Febbo is also founder of Plexuus, an early stage payment processing platform for medical professionals with Sunshine Act-related activities.
Febbo holds a Bachelor of Arts in International Studies from Dickinson College, in Pennsylvania and serves on the board of The United Nations of Greater Boston, a non-profit focused on building global citizens within inner-city schools in Massachusetts.
Febbo has joined MIT linQ as a faculty member. LinQ is a new collaborative initiative focused on increasing the potential of innovative research to benefit society and the economy. linQ’s portfolio of international innovation programs demonstrates a new paradigm for technology research and training. Thus far, Febbo has participated in two of these programs, IMPACT and Idea2 global.
Currently, he holds the position of CEO at OptimizeRx and continues to discover, innovate, and connect both products and people to meaningful experiences to improve health outcomes.